This study, presented at ICAAC 2014, found no difference in calcium scores -- a predictor of coronary artery disease -- between HIV-positive people on long-term antiretroviral therapy and the general population.
Only 1 in 10 veterans diagnosed with hepatitis C (HCV) or HIV/HCV coinfection in the Veterans Administration (VA) Medical Center got treated for HCV in a 2008-2013 analysis.
Chronic obstructive pulmonary disease (COPD) has been a leading cause of death globally (currently third highest) for at least the last 25 years. The main risk factor for COPD is cigarette smoking.
Initiation of antiretroviral therapy usually leads to increased weight and body mass index (BMI) that might be associated with an increased risk of cardiovascular disease and type-2 diabetes.
IFARA interviewed Mark Sulkowski, M.D., of Johns Hopkins University School of Medicine about new advances in hepatitis C screening and treatment.
Chronic obstructive pulmonary disease (COPD) was found in 9% of people living with HIV in a large French cohort -- and 77% of the cases were previously undiagnosed.
Two studies examine the often overlooked hepatitis C (HCV) risk among HIV-negative men who have sex with men (MSM). While the incidence of HCV doesn’t appear to be great, screening is still uncommon and we may just be beginning to identify new cases....
Amidst the clamor and excitement of the ongoing hepatitis C (HCV) treatment renaissance, one word is rarely uttered: vaccine. But the hunt goes on, quietly -- and with great difficulty.
An oral, interferon-free combination of three drugs (ABT-450, ombitasvir and dasabuvir), administered with or without ribavirin, achieved a sustained virologic response 12 weeks post treatment (SVR12) in 99% of patients with chronic hepatitis C.
Data from a large cohort reveal much variability in mean weight gains after initiating ART, depending on the weight category before going on treatment.